Volumina Medical secures USD 21 million funding to continue its clinical program after having obtained promising First-in-Human data

Volumina Medical, a clinical stage MedTech company developing novel biomaterials for dermatology and plastic surgery, announced the successful closing of its Series A financing round with the participation of existing and new investors. This financing will enable Volumina Medical to confidently advance its clinical program with its lead product AdipearlTM, and ultimately achieve market approval in key international markets.

Lenz & Staehelin has advised Volumina Medical in this financing round. The team was led by Federico Trabaldo Togna (Corporate and M&A) and included Sevan Antreasyan (IP, Commercial Contracts), Victor Sellier (Corporate and M&A), as well as Floran Ponce and Kimberly Hundt (both Tax).